| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Johnston John Joseph is a Director at MXCT. Recent filings cover 0 purchases and 21 sales.
Our model assigns Johnston John Joseph a strong insider score of 75/100, based on 21 past trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +29.4%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 27, 2025 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $4.65 | $13,935.00 | -2.1% | -35.4% | -76.3% | |
| Dec 26, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $4.01 | $12,021.00 | -2.1% | -31.7% | -60.4% | |
| Dec 9, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $3.78 | $11,327.55 | -2.1% | -18.0% | -63.1% | |
| Oct 28, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $3.72 | $11,166.00 | -2.1% | +25.2% | -57.1% | |
| Sep 26, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $3.82 | $11,460.00 | -2.1% | +4.6% | -60.7% | |
| Aug 26, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $4.28 | $12,840.00 | -2.1% | -16.6% | -67.9% | |
| Jul 26, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 3,000 | $4.75 | $14,238.00 | -2.1% | -20.7% | -53.0% | |
| Jun 27, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 10,000 | $3.99 | $39,900.00 | -6.6% | -4.7% | -45.0% | |
| Mar 26, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 5,000 | $4.41 | $22,025.00 | -4.0% | -3.5% | -35.9% | |
| Feb 26, 2024 | MXCT Maxcyte, Inc. | Director | Sale+OE | 5,000 | $4.60 | $23,005.00 | -4.0% | +6.4% | -20.3% |